Listed

Ecolab Inc.: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 4, 2022 and accepted by EDGAR at Nov 4, 2022, 08:00 ET.

Share

Management's discussion and analysis

As filed, 90,536 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following management discussion and analysis (“MD&A”) provides information we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The MD&A should be read in conjunction with both the unaudited consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2021. This discussion contains various Non-GAAP Financial Measures and also contains various Forward-Looking Statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Statements” located at the end of Part I of this report.

Comparability of Results

Purolite Acquisition

On December 1, 2021, we acquired Purolite Corporation (“Purolite”) for total consideration of $3.7 billion in cash. Purolite is a leading and fast-growing global provider of high-end ion exchange resins for the separation and purification of solutions for pharmaceutical and industrial applications. Headquartered in King of Prussia, Pennsylvania, Purolite operates in more than 30 countries. Purolite is reported within our Life Sciences operating segment. Acquisition and integration charges are recorded within special (gains) and charges. Amortization of acquisition-related intangible assets is recorded in the Corporate reportable segment.

Impact of Acquisitions and Divestitures

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and the results of our divested businesses from the twelve months prior to divestiture. As part of the separation of ChampionX in 2020, we entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

Fixed Currency Foreign Exchange Rates

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the “Segment Performance” section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

OVERVIEW OF THE THIRD QUARTER ENDED SEPTEMBER 30, 2022

Sales Performance

When comparing third quarter 2022 against third quarter 2021, sales performance was as follows:

  • Reported net sales increased 10% to $3,669.3 million, fixed currency sales increased 16% and acquisition adjusted fixed currency sales increased 13%.
  • Fixed currency sales for our Global Industrial segment increased 16% to $1,816.7 million, as strong double-digit growth across all divisions was driven by accelerating total pricing and new business wins.
  • Fixed currency sales for our Global Institutional & Specialty segment increased 12% to $1,183.2 million. Continued double-digit growth in the Institutional division reflected accelerating total pricing and volume growth. Specialty sales showed good growth, driven by strong quickservice sales growth.
  • Fixed currency sales for our Global Healthcare & Life Sciences segment increased 34% to $375.5 million. Acquisition adjusted fixed currency sales were flat as growth in Life Sciences was offset by slightly lower Healthcare sales. Healthcare’s decline reflected accelerating total pricing that were offset by continued softness in Europe.
  • Fixed currency sales and acquisition adjusted fixed currency sales for Other increased 13% to $362.1 million reflecting double-digit growth in Pest Elimination, Textile Care and Colloidal Technologies.

Financial Performance

When comparing third quarter 2022 against third quarter 2021, our financial performance was as follows:

  • Reported operating income increased 4% to $483 million. Excluding the impact of special (gains) and charges from both 2022 and 2021 reported results, adjusted operating income decreased 3% and our adjusted fixed currency operating income increased 2%.
  • Net income attributable to Ecolab increased 7% to $347.1 million. Excluding the impact of special (gains) and charges and discrete tax items from both 2022 and 2021 reported results, our adjusted net income attributable to Ecolab decreased 7%.
  • Reported diluted EPS increased 8% to $1.21. Excluding the impact of special (gains) and charges and discrete tax items from both 2022 and 2021 reported results, adjusted diluted EPS decreased 6% to $1.30 in the third quarter of 2022.
  • Our reported tax rate was 14.6% during the third quarter of 2022, compared to 18.3% during the third quarter of 2021. Excluding the tax rate impact of special (gains) and charges and discrete tax items from both 2022 and 2021 results, our adjusted tax rate was 18.3% during the third quarter of 2022, compared to 19.5% during the third quarter of 2021.

RESULTS OF OPERATIONS

Net Sales

​ ​ ​ (millions) ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Change
Product and equipment sales ​ ​ $2,963.0 ​ ​ ​ $2,653.8 ​ ​ ​ ​ ​ ​ $8,473.9 ​ ​ ​ $7,461.6 ​ ​ ​
Service and lease sales ​ ​ 706.3 ​ ​ ​ 667.0 ​ ​ ​ ​ ​ ​ 2,042.7 ​ ​ ​ 1,906.9 ​ ​ ​
Reported GAAP net sales ​ ​ $3,669.3 ​ ​ ​ $3,320.8 ​ 10% ​ ​ ​ $10,516.6 ​ ​ ​ $9,368.5 ​ 12%
Effect of foreign currency translation ​ 96.0 ​ ​ ​ (64.1) ​ ​ ​ ​ ​ 120.3 ​ ​ ​ (210.9) ​ ​ ​
Non-GAAP fixed currency sales ​ ​ $3,765.3 ​ ​ ​ $3,256.7 ​ 16% ​ ​ ​ $10,636.9 ​ ​ ​ $9,157.6 ​ 16%

Product and sold equipment revenue is generated from providing cleaning, sanitizing and water treatment products or selling equipment used in combination with specialized products. Service and lease equipment revenue is generated from providing services or leasing equipment to customers. All of our sales are subject to the same economic conditions.

The percentage components of the period-over-period 2022 sales change are shown below:

​ ​ ​ ​ ​ ​ (percent) ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​
Volume ​ ​ 1% ​ ​ ​ 4% ​
Price changes ​ ​ 12 ​ ​ ​ ​ 9 ​ ​
Acquisition adjusted fixed currency sales change ​ ​ 13 ​ ​ ​ ​ 13 ​ ​
Acquisitions and divestitures ​ ​ 3 ​ ​ ​ ​ 4 ​ ​
Fixed currency sales change ​ ​ 16 ​ ​ ​ ​ 16 ​ ​
Foreign currency translation ​ ​ (5) ​ ​ ​ ​ (4) ​ ​
Reported GAAP net sales change ​ ​ 10% ​ ​ ​ 12% ​

Amounts do not necessarily sum due to rounding.

Cost of Sales (“COS”) and Gross Profit Margin

​ ​ ​ ​ ​ (millions/percent) ​ Third Quarter Ended September 30 2022 COS ​ ​ ​ ​ ​ ​ Gross Margin ​ ​ ​ ​ ​ 2021 COS ​ ​ ​ ​ ​ ​ Gross Margin ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 COS ​ ​ ​ ​ ​ ​ Gross Margin ​ ​ ​ ​ ​ 2021 COS ​ ​ ​ ​ ​ ​ Gross Margin
Product and equipment cost of sales ​ $1,877.1 ​ ​ ​ ​ ​ ​ $1,625.1 ​ ​ ​ ​ ​ ​ $5,371.7 ​ ​ ​ ​ ​ ​ $4,452.9 ​ ​ ​ ​
Service and lease cost of sales ​ 414.5 ​ ​ ​ ​ ​ ​ 391.6 ​ ​ ​ ​ ​ ​ 1,204.4 ​ ​ ​ ​ ​ ​ 1,119.8 ​ ​ ​ ​
Reported GAAP COS and gross margin ​ $2,291.6 ​ ​ 37.5% ​ ​ $2,016.7 ​ ​ 39.3% ​ ​ $6,576.1 ​ ​ 37.5% ​ ​ $5,572.7 ​ ​ 40.5%
Special (gains) and charges ​ 7.1 ​ ​ ​ ​ ​ 52.9 ​ ​ ​ ​ ​ 61.7 ​ ​ ​ ​ ​ 76.2 ​ ​ ​
Non-GAAP adjusted COS and gross margin ​ $2,284.5 ​ ​ 37.7% ​ ​ $1,963.8 ​ ​ 40.9% ​ ​ $6,514.4 ​ ​ 38.1% ​ ​ $5,496.5 ​ ​ 41.3%

Our COS and corresponding gross profit margin (“gross margin”) are shown in the table above. Gross margin is defined as net sales less cost of sales divided by net sales.

Our reported gross margin was 37.5% and 39.3% for the third quarter of 2022 and 2021, respectively. Our reported gross margin was 37.5% and 40.5% for the first nine months of 2022 and 2021, respectively. Special (gains) and charges included in items impacting cost of sales are shown within the “Special (Gains) and Charges” table below.

Excluding the impact of special (gains) and charges within cost of sales, third quarter 2022 adjusted gross margin was 37.7% and our adjusted gross margin for the first nine months of 2022 was 38.1%. These percentages compared against a third quarter 2021 adjusted gross margin of 40.9% and an adjusted gross margin of 41.3% for the first nine months of 2021.

Our adjusted gross margin decreased when comparing the third quarter and first nine months of 2022 against the third quarter and first nine months of 2021, primarily reflecting accelerating total pricing that was more than offset by a significant increase in delivered product cost inflation and unfavorable mix.

Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expenses as a percentage of sales were 23.9% and 26.0% for the third quarter and first nine months of 2022, respectively, compared to 25.1% and 27.2% for the third quarter and first nine months of 2021, respectively. The SG&A ratio to sales in the third quarter and first nine months of 2022 decreased driven by sales leverage and cost savings that more than offset investments in the business.

Special (Gains) and Charges

Special (gains) and charges reported on the Consolidated Statements of Income include the following items:

​ ​ ​ (millions) Cost of sales ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​
Restructuring activities ​ ​ $2.1 ​ ​ ​ $2.2 ​ ​ $5.5 ​ ​ $24.1 ​
Acquisition and integration activities ​ ​ 4.2 ​ ​ ​ - ​ ​ 32.7 ​ ​ ​ - ​
COVID-19 activities, net ​ ​ - ​ ​ ​ 50.7 ​ ​ 16.3 ​ ​ ​ 51.8 ​
Russia/Ukraine activities ​ ​ 0.8 ​ ​ ​ - ​ ​ 7.2 ​ ​ ​ - ​
Other ​ ​ - ​ ​ ​ - ​ ​ - ​ ​ ​ 0.3 ​
Cost of sales subtotal ​ ​ 7.1 ​ ​ ​ 52.9 ​ ​ 61.7 ​ ​ 76.2 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Restructuring activities ​ ​ (0.3) ​ ​ ​ 0.4 ​ ​ 0.8 ​ ​ 6.5 ​
Acquisition and integration activities ​ ​ 4.1 ​ ​ ​ 0.8 ​ ​ 15.0 ​ ​ ​ 3.3 ​
COVID-19 activities, net ​ ​ 2.5 ​ ​ ​ 1.5 ​ ​ 7.1 ​ ​ 16.2 ​
Russia/Ukraine activities ​ ​ - ​ ​ ​ - ​ ​ 5.9 ​ ​ ​ - ​
Other ​ ​ 11.5 ​ ​ ​ 3.6 ​ ​ 16.7 ​ ​ 10.7 ​
Special (gains) and charges subtotal ​ ​ 17.8 ​ ​ ​ 6.3 ​ ​ 45.5 ​ ​ 36.7 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income subtotal ​ ​ 24.9 ​ ​ ​ 59.2 ​ ​ 107.2 ​ ​ ​ 112.9 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Other (income) expense ​ ​ 24.8 ​ ​ ​ 7.0 ​ ​ 24.8 ​ ​ ​ 26.6 ​
Interest expense, net ​ ​ - ​ ​ ​ 32.3 ​ ​ - ​ ​ ​ 32.3 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total special (gains) and charges ​ ​ $49.7 ​ ​ ​ $98.5 ​ ​ $132.0 ​ ​ ​ $171.8 ​

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting.

Restructuring activities

Restructuring activities relate to the Institutional Advancement Program, Accelerate 2020 and other immaterial restructuring programs which are described below. These activities have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

Further details related to our restructuring charges are included in Note 2.

Institutional Advancement Program

We approved a restructuring plan in 2020 focused on the Institutional business (“the Institutional Plan”) which is intended to enhance our Institutional sales and service structure and allow the sales team to capture share and penetration while maximizing service effectiveness by leveraging our ongoing investments in digital technology. In February 2021, we expanded the Institutional Plan, and we expect that these restructuring charges will be completed by 2023, with total anticipated costs of $70 million ($55 million after tax) or $0.19 per diluted share. The remaining costs are expected to be primarily cash expenditures for severance and non-cash charges related to equipment disposals. Actual costs may vary from these estimates depending on actions taken.

In the third quarter and first nine months of 2022, we recorded restructuring charges of $1.8 million ($1.3 million after tax) or less than $0.01 per diluted share and $3.9 million ($2.9 million after tax) or $0.01 per diluted share, respectively, primarily related to severance, disposals of equipment and office closures. We have recorded $51.7 million ($39.5 million after tax), or $0.14 per diluted share of cumulative restructuring charges under the Institutional Plan. The liability related to the Institutional Plan was $2.2 million as of September 30, 2022. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Institutional Plan has delivered $48 million of cumulative cost savings with estimated annual cost savings of $55 million by 2024.

Accelerate 2020

During 2018, we formally commenced a restructuring plan Accelerate 2020 (“the Plan”), to leverage technology and system investments and organizational changes. The goals of the Plan are to further simplify and automate processes and tasks, reduce complexity and management layers, consolidate facilitates and focus on key long-term growth areas by further leveraging technology and structural improvements. During 2020, we expanded the Plan for additional costs and savings to further leverage the technology and structural improvements. Following the establishment of the separate Institutional Plan, we now expect that the restructuring activities will be completed by the end of 2022, with total anticipated costs of $255 million ($195 million after tax), or $0.68 per diluted share. Remaining costs are expected to be primarily cash expenditures for severance costs and some facility closure costs relating to team reorganizations. Actual costs may vary from these estimates depending on actions taken.

We recorded restructuring charges (gains) of ($0.6) million ($0.3 million after tax), or less than $0.01 per diluted share and $1.5 million ($1.2 million after tax), or less than $0.01 per diluted share in the third quarter of 2022 and 2021, respectively and ($0.2) million ($0.1 million after tax), or less than $0.01 per diluted share and $2.9 million ($2.8 million after tax), or $0.01 per diluted share in the first nine months of 2022 and 2021, respectively. The liability related to the Plan was $15.5 million as of the end of the third quarter of 2022. We have recorded $244.3 million ($189.9 million after tax), or $0.66 per diluted share, of cumulative restructuring charges under the Plan. The majority of the pretax charges represent net cash expenditures which are expected to be paid over a period of a few months to several quarters which continue to be funded from operating activities.

The Plan has delivered $315 million of cumulative cost savings with estimated annual cost savings of $315 million by 2022.

Other Restructuring Activities

During the third quarter of 2022 and 2021, we incurred restructuring charges (gains) of $0.6 million ($0.5 million after tax), or less than $0.01 per diluted share and ($0.3) million ($0.5 million after tax), or less than $0.01 per diluted share, respectively, and during the first nine months of 2022 and 2021, we incurred $2.6 million ($2.0 million after tax), or less than $0.01 per diluted share and $18.2 million ($16.9 million after tax), or $0.06 per diluted share, respectively, related to other immaterial restructuring activity. The charges primarily related to severance and asset write-offs.

The restructuring liability balance for all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $4.0 million and $4.6 million as of September 30, 2022 and December 31, 2021, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during the third quarter of 2022 related to all other restructuring plans excluding the Accelerate 2020 and Institutional Plan were $3.2 million.

Acquisition and integration related costs

Acquisition and integration related costs reported in product and equipment cost of sales on the Consolidated Statements of Income in the third quarter and first nine months of 2022 include $4.2 million ($3.9 million after tax) or $0.01 per diluted share and $32.7 million ($25.8 million after tax) or $0.09 per diluted share, respectively, and are related primarily to the recognition of fair value step-up in the Purolite inventory and other integration costs.

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income include $4.1 million ($3.9 million after tax) or $0.01 per diluted share and $15.0 million ($11.9 million after tax) or $0.04 per diluted share in the third quarter and first nine months of 2022, respectively. Charges are related to Purolite, Copal Invest NV, including its primary operating entity CID Lines (collectively, “CID Lines”), and Bioquell PLC (“Bioquell”) acquisitions and consist of integration related costs, advisory and legal fees.

Acquisition and integration costs reported in special (gains) and charges on the Consolidated Statements of Income include $0.8 million ($0.8 million after tax) or less than $0.01 per diluted share and $3.3 million ($2.9 million after tax) or $0.01 per diluted share in the third quarter and first nine months of 2021, respectively. Charges are related to CID Lines, and Bioquell acquisitions and consist of integration costs, advisory and legal fees.

COVID-19 activities

We recorded charges of $1.3 million during the third quarter and first nine months of 2022 to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $1.6 million and $7.7 million related to employee COVID-19 testing and related expenses during the third quarter and first nine months of 2022, respectively. In addition, we received immaterial amounts of subsidies and government assistance which were recorded in special (gains) and charges in the first nine months of both 2022 and 2021. We recorded $15 million in inventory reserves related to excess sanitizer inventory and estimated disposal costs during the first quarter of 2022. COVID-19 pandemic charges are recorded in product and equipment cost of sales and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges related to the COVID-19 pandemic were $2.1 million or less than $0.01 per diluted share and $17.9 million or $0.06 per diluted share during the third quarter and first nine months of 2022, respectively.

During the third quarter and first nine months of 2021, we recorded charges of $2.6 million and $12.6 million, respectively, to protect the wages of certain employees directly impacted by the COVID-19 pandemic. We also recorded charges of $3.1 million and $11.5 million, respectively, during the third quarter and first nine months of 2021 related to COVID-19 testing and related expenses. In addition, we received subsidies and government assistance, which were recorded as special (gains) and charges of ($3.5) million and ($6.1) million during the third quarter and first nine months of 2021, respectively. COVID-19 pandemic charges are recorded in product and equipment sales, service and lease sales, and special (gains) and charges on the Consolidated Statements of Income. Total after tax net charges related to COVID-19 pandemic were $40.6 million or $0.14 per diluted share and $51.9 million or $0.18 per diluted share during the third quarter and first nine months of 2021, respectively.

Russia/Ukraine activities

In light of Russia’s invasion of Ukraine and the sanctions against Russia by the United States and other countries, we have made the determination that we will limit our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We recorded charges of $0.8 million ($0.7 million after tax) or less than $0.01 per diluted share and charges of $13.1 million ($14.0 million after tax) or $0.05 per diluted share in the third quarter and first nine months of 2022, respectively, primarily related to recoverability risk of certain assets in both Russia and Ukraine.

Other operating activities

Other special charges recorded in the third quarter and first nine months of 2022 in special (gains) and charges on the Consolidated Statements of Income were $11.5 million ($8.7 million after tax) or $0.03 per diluted share and $16.7 million ($12.6 million after tax) or $0.04 per diluted share, respectively, primarily related to certain legal charges.

Other special charges of $3.6 million ($2.7 million after tax) or $0.01 per diluted share and $10.7 million ($8.3 million after tax) or $0.03 per diluted share recorded in the third quarter and first nine months of 2021, respectively, related to certain legal charges in addition to tax consulting fees associated with the ChampionX separation, which are recorded in special (gains) and charges and product and equipment cost of sales on the Consolidated Statements of Income.

Other (income) expense

We incurred settlement expense recorded in other expense (income) on the Consolidated Statements of Income of $24.8 million ($18.8 million after tax) or $0.07 per diluted share and $7.0 million ($5.3 million after tax) or $0.02 per diluted share during the third quarter of 2022 and 2021, respectively, and $24.8 million ($18.8 million after tax) or $0.07 per diluted share and $26.6 million ($20.2 million after tax) or $0.07 per diluted share during the first nine months of 2022 and 2021, respectively. Expenses are related to U.S. pension plan lump-sum payments to retirees.

Interest expense

During the third quarter of 2021, we recorded special charges of $32.3 million ($28.4 million after tax) or $0.10 per diluted share in interest expense on the Consolidated Statement of Income primarily related to debt refinancing charges.

Operating Income and Operating Income Margin

​ ​ ​ (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 2021 ​ ​ Change ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 2021 ​ ​ Change ​ ​ ​
Reported GAAP operating income ​ ​ $483.0 ​ ​ ​ $465.8 ​ ​ 4% ​ ​ ​ $1,163.3 ​ ​ ​ $1,210.9 ​ ​ (4)% ​
Special (gains) and charges ​ 24.9 ​ ​ 59.2 ​ ​ ​ ​ ​ ​ 107.2 ​ ​ 112.9 ​ ​ ​ ​ ​
Non-GAAP adjusted operating income ​ 507.9 ​ ​ 525.0 ​ ​ (3)% ​ ​ 1,270.5 ​ ​ 1,323.8 ​ ​ (4)% ​
Effect of foreign currency translation ​ 15.0 ​ ​ (12.7) ​ ​ ​ ​ ​ ​ 18.6 ​ ​ (38.7) ​ ​ ​ ​ ​
Non-GAAP adjusted fixed currency operating income ​ ​ $522.9 ​ ​ ​ $512.3 ​ ​ 2% ​ ​ ​ $1,289.1 ​ ​ ​ $1,285.1 ​ ​ 0% ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ Third Quarter Ended ​ ​ ​ ​ ​ Nine Months Ended ​ ​ ​ ​
​ ​ September 30 ​ ​ ​ ​ ​ September 30 ​ ​ ​ ​
(percent) ​ 2022 ​ 2021 ​ ​ ​ ​ ​ 2022 ​ 2021 ​ ​ ​ ​
Reported GAAP operating income margin ​ ​ 13.2% ​ ​ 14.0% ​ ​ ​ ​ ​ ​ 11.1% ​ ​ 12.9% ​ ​ ​ ​
Non-GAAP adjusted operating income margin ​ ​ 13.8% ​ ​ 15.8% ​ ​ ​ ​ ​ ​ 12.1% ​ ​ 14.1% ​ ​ ​ ​
Non-GAAP adjusted fixed currency operating income margin ​ ​ 13.9% ​ ​ 15.7% ​ ​ ​ ​ ​ ​ 12.1% ​ ​ 14.0% ​ ​ ​ ​

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by net sales.

Our reported operating income increased 4% and decreased 4% in the third quarter and first nine months of 2022, respectively, versus the comparable period of 2021. Our reported operating income for 2022 and 2021 was impacted by special (gains) and charges; excluding the impact of special (gains) and charges from 2022 and 2021 reported results, our adjusted operating income decreased 3% and 4% in the third quarter and first nine months of 2022, respectively.

As shown in the previous table, foreign currency had a 5 and 4 percentage points impact on adjusted operating income growth for the third quarter and first nine months of 2022, respectively. Foreign currency had a 2 and 4 percentage points impact on adjusted operating income growth for the third quarter and first nine months of 2021, respectively.

Other (Income) Expense

​ ​ ​ (millions) ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ Change
Reported GAAP other (income) expense ​ ​ $5.7 ​ ​ ​ ($13.0) ​ (144)% ​ ​ ($32.6) ​ ​ ​ ($27.5) ​ 19%
Special (gains) and charges ​ ​ 24.8 ​ ​ 7.0 ​ ​ ​ ​ ​ 24.8 ​ ​ 26.6 ​ ​ ​
Non-GAAP adjusted other (income) expense ​ ​ ($19.1) ​ ​ ​ ($20.0) ​ (4)% ​ ​ ($57.4) ​ ​ ​ ($54.1) ​ 6%

Other expense (income) was $5.7 million and ($13.0) million in the third quarter of 2022 and 2021, respectively. Other income was $32.6 million and $27.5 million in the first nine months of 2022 and 2021, respectively. We recognized pension settlement expense of $24.8 million in special (gains) and charges in third quarter and first nine months of 2022, and $7.0 million and $26.6 million in third quarter and first nine months of 2021, respectively.

Interest Expense, Net

​ ​ ​ (millions) ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ Change
Reported GAAP interest expense, net ​ ​ $65.1 ​ ​ ​ $76.4 ​ (15)% ​ ​ $174.1 ​ ​ ​ $173.7 ​ 0%
Special (gains) and charges ​ ​ - ​ ​ 32.3 ​ ​ ​ ​ ​ - ​ ​ 32.3 ​ ​ ​
Non-GAAP adjusted interest expense, net ​ ​ $65.1 ​ ​ ​ $44.1 ​ 48% ​ ​ $174.1 ​ ​ ​ $141.4 ​ 23%

Reported net interest expense was $65.1 million and $76.4 million in the third quarter of 2022 and 2021, respectively. Reported net interest expense was $174.1 million and $173.7 million in the first nine months of 2022 and 2021, respectively. In the third quarter of 2021, we incurred $32.3 million of expense associated with debt refinancing. Adjusted for debt refinancing costs, the increase in interest expense when comparing 2022 against 2021 was driven primarily by the interest on debt issued to fund the Purolite acquisition and the impact from higher average interest rates on floating rate debt.

Provision for Income Taxes

The following table provides a summary of our tax rate:

​ ​ ​ (percent) ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ 2021
Reported GAAP tax rate ​ 14.6% ​ 18.3% ​ 17.9% ​ 21.2%
Tax rate impact of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges 0.6 ​ ​ - ​ ​ 0.2 ​ ​ (0.3)
Discrete tax items 3.1 ​ ​ 1.2 ​ ​ 0.8 ​ ​ (1.4)
Non-GAAP adjusted tax rate 18.3% ​ 19.5% 18.9% ​ 19.5%

Our reported tax rate was 14.6% and 18.3% for the third quarter of 2022 and 2021, respectively and 17.9% and 21.2% for the first nine months of 2022 and 2021, respectively. The change in our tax rate for the third quarter and first nine months of 2022 versus the comparable period of 2021 was driven primarily by discrete tax items and special (gains) and charges. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized a net tax benefit related to discrete tax items of $14.2 million and $9.5 million in the third quarter and first nine months of 2022, respectively. This included a deferred tax benefit of $14.6 million associated with utilization of tax attributes as a result of legal entity rationalization and share-based compensation excess tax benefits of $0.7 million and $4.3 million in the third quarter and first nine months of 2022, respectively. The amount of the excess tax benefit is subject to variation in stock price and award exercises. Additionally, we recognized discrete tax expense of $1.1 million and $9.4 million in the third quarter and first nine months of 2022, respectively, primarily due to audit settlements, reserves for uncertain tax positions, prior year return adjustments, repricing of deferred tax balances, and other changes in estimates.

We recognized a net tax benefit related to discrete tax items of $6.3 million in the third quarter and a net tax expense of $17.5 million in the first nine months of 2021. This included a tax benefit of $4.0 million in the third quarter and a net tax expense of $5.5 million in the first nine months of 2021 related to prior year returns, and a deferred tax benefit of $0.4 million and deferred tax expense of $23.8 million associated with transferring certain intangible property between affiliates in the third quarter and first nine months of 2021, respectively. The share-based compensation excess tax benefit was $9.9 million and $20.7 million in the third quarter and first nine months of 2021, respectively. The remaining discrete tax expense of $8.0 million and $8.9 million during the quarter and first nine months of 2021, respectively, was primarily due to changes in tax law, reserves for uncertain tax positions, audit settlements, and other changes in estimates.

The decrease in the third quarter and first nine months of 2022 adjusted tax rate compared to 2021 was primarily due to the geographic mix of income and tax planning.

Net Income Attributable to Ecolab

​ ​ ​ (millions) ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ Change ​ ​ ​
Reported GAAP net income attributable to Ecolab ​ ​ $347.1 ​ ​ ​ $324.5 ​ ​ 7% ​ ​ ​ $827.3 ​ ​ ​ $828.9 ​ ​ (0)% ​
Adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges, after tax ​ 39.6 ​ ​ ​ 80.8 ​ ​ ​ ​ ​ ​ ​ 105.8 ​ ​ ​ 139.1 ​ ​ ​ ​ ​
Discrete tax net expense ​ (14.2) ​ ​ ​ (6.3) ​ ​ ​ ​ ​ ​ ​ (9.5) ​ ​ ​ 17.5 ​ ​ ​ ​ ​
Non-GAAP adjusted net income attributable to Ecolab ​ ​ $372.5 ​ ​ ​ $399.0 ​ ​ (7)% ​ ​ ​ $923.6 ​ ​ ​ $985.5 ​ ​ (6)% ​

Diluted EPS

​ ​ ​ (dollars) ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ Change ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ 2021 ​ ​ ​ Change ​ ​ ​
Reported GAAP diluted EPS ​ ​ $1.21 ​ ​ ​ $ 1.12 ​ ​ 8% ​ ​ ​ $2.88 ​ ​ ​ $ 2.87 ​ ​ 0% ​
Adjustments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Special (gains) and charges, after tax ​ 0.14 ​ ​ ​ 0.28 ​ ​ ​ ​ ​ ​ ​ 0.37 ​ ​ ​ 0.48 ​ ​ ​ ​ ​
Discrete tax net expense ​ (0.05) ​ ​ ​ (0.02) ​ ​ ​ ​ ​ ​ ​ (0.03) ​ ​ ​ 0.06 ​ ​ ​ ​ ​
Non-GAAP adjusted diluted EPS ​ ​ $1.30 ​ ​ ​ $ 1.38 ​ ​ (6)% ​ ​ ​ $3.22 ​ ​ ​ $ 3.41 ​ ​ (6)% ​

Per share amounts in the above tables do not necessary sum due to rounding.

Currency translation had an unfavorable impact of approximately ($0.08) and ($0.17) per share on diluted EPS for the third quarter and first nine months of 2022, respectively, when compared to the comparable periods of 2021.

SEGMENT PERFORMANCE

The non-U.S. dollar functional international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates used by management for 2022. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as “effect of foreign currency translation” in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2 of our Annual Report on Form 10-K for the year ended December 31, 2021. Additional information about our reportable segments is included in Note 15.

Fixed currency net sales and operating income for the third quarter and first nine months of 2022 and 2021 for our reportable segments are shown in the following tables:

​ Net Sales ​ (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 2021 ​ ​ Change ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 2021 ​ ​ Change
Global Industrial ​ ​ $1,816.7 ​ ​ $1,565.0 ​ 16% ​ ​ $5,077.8 ​ ​ $4,452.2 ​ 14%
Global Institutional & Specialty ​ 1,183.2 ​ ​ 1,057.1 ​ ​ 12 ​ ​ 3,323.4 ​ ​ 2,864.7 ​ ​ 16 ​
Global Healthcare & Life Sciences ​ ​ 375.5 ​ ​ ​ 279.7 ​ ​ 34 ​ ​ ​ 1,138.9 ​ ​ ​ 852.8 ​ ​ 34 ​
Other ​ ​ 362.1 ​ ​ ​ 319.5 ​ ​ 13 ​ ​ ​ 1,000.4 ​ ​ ​ 885.2 ​ ​ 13 ​
Corporate ​ 27.8 ​ ​ 35.4 ​ ​ (21) ​ ​ 96.4 ​ ​ 102.7 ​ ​ (6) ​
Subtotal at fixed currency ​ 3,765.3 ​ ​ 3,256.7 ​ ​ 16 ​ ​ 10,636.9 ​ ​ 9,157.6 ​ ​ 16 ​
Effect of foreign currency translation ​ (96.0) ​ ​ 64.1 ​ ​ ​ ​ ​ (120.3) ​ ​ 210.9 ​ ​ ​ ​
Consolidated reported GAAP net sales ​ $3,669.3 ​ ​ ​ $3,320.8 ​ ​ 10% ​ $10,516.6 ​ ​ ​ $9,368.5 ​ ​ 12%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating Income ​ Third Quarter Ended ​ Nine Months Ended
​ ​ September 30 ​ September 30
(millions) ​ 2022 2021 ​ ​ Change ​ 2022 2021 ​ ​ Change
Global Industrial $277.0 ​ ​ $258.6 ​ 7% ​ $693.2 ​ ​ $719.7 ​ (4)%
Global Institutional & Specialty ​ 199.1 ​ ​ 190.9 ​ 4 ​ ​ ​ 462.5 ​ ​ 390.5 ​ 18 ​
Global Healthcare & Life Sciences ​ ​ 34.7 ​ ​ ​ 35.2 ​ ​ (1) ​ ​ ​ 137.3 ​ ​ ​ 123.9 ​ ​ 11 ​
Other ​ 64.4 ​ ​ 57.8 ​ 11 ​ ​ ​ 153.6 ​ ​ 140.9 ​ 9 ​
Corporate ​ (77.2) ​ ​ (89.4) ​ ​ (14) ​ ​ ​ (264.7) ​ ​ (202.8) ​ ​ 31 ​
Subtotal at fixed currency ​ 498.0 ​ ​ 453.1 ​ 10 ​ ​ ​ 1,181.9 ​ ​ 1,172.2 ​ 1 ​
Effect of foreign currency translation ​ (15.0) ​ ​ 12.7 ​ ​ ​ ​ ​ ​ (18.6) ​ ​ 38.7 ​ ​ ​ ​
Consolidated reported GAAP operating income $483.0 ​ ​ ​ $465.8 ​ 4% ​ $1,163.3 ​ ​ ​ $1,210.9 ​ (4)%

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments:

​ ​ ​ Net Sales (millions) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ 2021 Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ ​ ​ ​
Global Industrial ​ $1,816.7 ​ ($7.9) ​ $1,808.8 ​ ​ $1,565.0 ​ $- ​ $1,565.0 ​
Global Institutional & Specialty 1,183.2 ​ - ​ 1,183.2 ​ ​ 1,057.1 ​ - ​ 1,057.1 ​
Global Healthcare & Life Sciences ​ 375.5 ​ (95.5) ​ 280.0 ​ ​ 279.7 ​ - ​ 279.7 ​
Other 362.1 ​ - ​ 362.1 ​ ​ 319.5 ​ - ​ 319.5 ​
Corporate 27.8 ​ (27.8) ​ - ​ ​ 35.4 ​ (35.4) ​ - ​
Subtotal at fixed currency 3,765.3 ​ (131.2) ​ 3,634.1 ​ ​ 3,256.7 ​ (35.4) ​ 3,221.3 ​
Effect of foreign currency translation (96.0) ​ ​ ​ ​ ​ ​ 64.1 ​ ​ ​ ​ ​
Total reported net sales $3,669.3 ​ ​ ​ ​ ​ ​ $3,320.8 ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating Income ​ 2022 ​ ​ 2021 ​
(millions) Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​
Global Industrial ​ $277.0 ​ ($1.3) ​ $275.7 ​ ​ $258.6 ​ $- ​ $258.6 ​
Global Institutional & Specialty 199.1 ​ - ​ 199.1 ​ ​ 190.9 ​ - ​ 190.9 ​
Global Healthcare & Life Sciences ​ 34.7 ​ (15.6) ​ 19.1 ​ ​ 35.2 ​ - ​ 35.2 ​
Other 64.4 ​ - ​ 64.4 ​ ​ 57.8 ​ - ​ 57.8 ​
Corporate (52.3) ​ 22.4 ​ (29.9) ​ ​ (30.2) ​ - ​ (30.2) ​
Non-GAAP adjusted fixed currency operating income 522.9 ​ 5.5 ​ 528.4 ​ ​ 512.3 ​ - ​ 512.3 ​
Special (gains) and charges 24.9 ​ ​ ​ ​ ​ ​ 59.2 ​ ​ ​ ​ ​
Subtotal at fixed currency 498.0 ​ ​ ​ ​ ​ ​ 453.1 ​ ​ ​ ​ ​
Effect of foreign currency translation (15.0) ​ ​ ​ ​ ​ ​ 12.7 ​ ​ ​ ​ ​
Total reported operating income $483.0 ​ ​ ​ ​ ​ ​ $465.8 ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ Nine Months Ended ​
​ ​ September 30 ​
Net Sales ​ 2022 ​ ​ 2021 ​
(millions) Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​
Global Industrial ​ $5,077.8 ​ ($21.0) ​ $5,056.8 ​ ​ $4,452.2 ​ $- ​ $4,452.2 ​
Global Institutional & Specialty 3,323.4 ​ - ​ 3,323.4 ​ ​ 2,864.7 ​ - ​ 2,864.7 ​
Global Healthcare & Life Sciences ​ 1,138.9 ​ (307.5) ​ 831.4 ​ ​ 852.8 ​ - ​ 852.8 ​
Other 1,000.4 ​ - ​ 1,000.4 ​ ​ 885.2 ​ - ​ 885.2 ​
Corporate ​ 96.4 ​ (96.4) ​ - ​ ​ 102.7 ​ (102.7) ​ - ​
Subtotal at fixed currency 10,636.9 ​ (424.9) ​ 10,212.0 ​ ​ 9,157.6 ​ (102.7) ​ 9,054.9 ​
Effect of foreign currency translation (120.3) ​ ​ ​ ​ ​ ​ 210.9 ​ ​ ​ ​ ​
Total reported net sales $10,516.6 ​ ​ ​ ​ ​ ​ $9,368.5 ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating Income ​ 2022 ​ ​ 2021 ​
(millions) Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​ ​ Fixed Currency ​ Impact of Acquisitions and Divestitures ​ Acquisition Adjusted ​
Global Industrial ​ $693.2 ​ ($3.4) ​ $689.8 ​ ​ $719.7 ​ $- ​ $719.7 ​
Global Institutional & Specialty 462.5 ​ - ​ 462.5 ​ ​ 390.5 ​ - ​ 390.5 ​
Global Healthcare & Life Sciences 137.3 ​ (65.1) ​ 72.2 ​ ​ 123.9 ​ - ​ 123.9 ​
Other ​ 153.6 ​ - ​ 153.6 ​ ​ 140.9 ​ - ​ 140.9 ​
Corporate (157.5) ​ 68.0 ​ (89.5) ​ ​ (89.9) ​ - ​ (89.9) ​
Non-GAAP adjusted fixed currency operating income 1,289.1 ​ (0.5) ​ 1,288.6 ​ ​ 1,285.1 ​ - ​ 1,285.1 ​
Special (gains) and charges 107.2 ​ ​ ​ ​ ​ ​ 112.9 ​ ​ ​ ​ ​
Subtotal at fixed currency 1,181.9 ​ ​ ​ ​ ​ ​ 1,172.2 ​ ​ ​ ​ ​
Effect of foreign currency translation (18.6) ​ ​ ​ ​ ​ ​ 38.7 ​ ​ ​ ​ ​
Total reported operating income $1,163.3 ​ ​ ​ ​ ​ ​ $1,210.9 ​ ​ ​ ​ ​

Unless otherwise noted, the following segment performance commentary compares the third quarter and first nine months of 2022 against the third quarter and first nine months of 2021.

Global Industrial

​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​
Sales at fixed currency (millions) ​ ​ $1,816.7 ​ ​ ​ $1,565.0 ​ ​ ​ $5,077.8 ​ ​ ​ $4,452.2 ​
Sales at public currency (millions) ​ ​ 1,769.6 ​ ​ ​ 1,603.1 ​ ​ ​ 5,025.2 ​ ​ ​ 4,578.6 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ -% ​ ​ ​ ​ 2% ​ ​ ​
Price changes ​ 15% ​ ​ ​ ​ 11% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ 16% ​ ​ ​ ​ ​ ​ 14% ​ ​ ​ ​
Acquisitions and divestitures ​ 1% ​ ​ ​ ​ -% ​ ​ ​
Fixed currency sales change ​ 16% ​ ​ ​ ​ 14% ​ ​ ​
Foreign currency translation ​ ​ (5)% ​ ​ ​ ​ ​ ​ (4)% ​ ​ ​ ​
Public currency sales change ​ 10% ​ ​ ​ ​ 10% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $277.0 ​ ​ ​ $258.6 ​ ​ ​ $693.2 ​ ​ ​ $719.7 ​
Operating income at public currency (millions) ​ ​ 269.0 ​ ​ ​ 267.1 ​ ​ ​ 684.2 ​ ​ ​ 748.2 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 7% ​ ​ ​ ​ ​ ​ (4)% ​ ​ ​ ​
Fixed currency operating income margin ​ 15.2% ​ 16.5% ​ 13.7% ​ 16.2%
Acquisition adjusted fixed currency operating income change ​ 7% ​ ​ ​ ​ (4)% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 15.2% ​ 16.5% ​ 13.6% ​ 16.2%
Public currency operating income change ​ ​ 1% ​ ​ ​ ​ ​ ​ (9)% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Global Industrial increased in both the third quarter and first nine months of 2022, as strong double-digit growth across all divisions was driven by accelerating total pricing and new business wins.

All operating segments reported double-digit growth, Water fixed currency sales increased 15% (14% acquisition adjusted) and 13% (12% acquisition adjusted) in the third quarter and first nine months of 2022, respectively, reflecting accelerating total pricing and new business wins. Light industry water treatment sales reported strong growth, driven by double-digit growth across data centers and microelectronics, food & beverage, manufacturing, and institutional. Heavy industry sales also recorded a strong increase led by double digit growth in power and chemicals. Mining showed very strong growth, benefiting from our strategic shift toward high-value metals and fertilizers, as well as strong new business wins. Food & Beverage fixed currency sales increased 14% and 12% in the third quarter and first nine months of 2022, respectively, reflecting accelerating total pricing. Downstream fixed currency sales increased 22% and 16% in the third quarter and first nine months of 2022, respectively, driven by accelerating pricing, new business wins and improved customer utilization rates. Paper fixed currency sales increased 19% and 17% in the third quarter and first nine months of 2022, respectively, driven by accelerating total pricing and new business wins.

Operating Income

Fixed currency operating income increased for the third quarter and decreased for first nine months of 2022, while fixed currency operating income margins decreased for Global Industrial in both the third quarter and first nine months of 2022.

Acquisition adjusted fixed currency operating income margins decreased 1.3 percentage points during the third quarter of 2022, as the 11.2 percentage point positive impacts of accelerating total pricing was more than offset by the 12.1 percentage points negative impacts of significantly higher Delivered Product Costs and unfavorable mix. Acquisition adjusted fixed currency operating income margins decreased 2.6 percentage points during the first nine months of 2022, as the 8.7 percentage point positive impacts of strong accelerating pricing were more than offset by the 12.0 percentage point negative impacts of significantly higher Delivered Product Costs and investments in the business.

Global Institutional & Specialty

​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​
Sales at fixed currency (millions) ​ ​ $1,183.2 ​ ​ ​ $1,057.1 ​ ​ ​ $3,323.4 ​ ​ ​ $2,864.7 ​
Sales at public currency (millions) ​ ​ 1,163.1 ​ ​ ​ 1,070.6 ​ ​ ​ 3,297.3 ​ ​ ​ 2,904.0 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ 2% ​ ​ ​ ​ 9% ​ ​ ​
Price changes ​ 10% ​ ​ ​ ​ 7% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ 12% ​ ​ ​ ​ ​ ​ 16% ​ ​ ​ ​
Acquisitions and divestitures ​ -% ​ ​ ​ ​ -% ​ ​ ​
Fixed currency sales change ​ 12% ​ ​ ​ ​ 16% ​ ​ ​
Foreign currency translation ​ ​ (3)% ​ ​ ​ ​ ​ ​ (2)% ​ ​ ​ ​
Public currency sales change ​ 9% ​ ​ ​ ​ 14% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $199.1 ​ ​ ​ $190.9 ​ ​ ​ $462.5 ​ ​ ​ $390.5 ​
Operating income at public currency (millions) ​ ​ 196.1 ​ ​ ​ 193.4 ​ ​ ​ 458.5 ​ ​ ​ 393.9 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 4% ​ ​ ​ ​ ​ ​ 18% ​ ​ ​ ​
Fixed currency operating income margin ​ 16.8% ​ 18.1% ​ 13.9% ​ 13.6%
Acquisition adjusted fixed currency operating income change ​ 4% ​ ​ ​ ​ 18% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 16.8% ​ 18.1% ​ 13.9% ​ 13.6%
Public currency operating income change ​ ​ 1% ​ ​ ​ ​ ​ ​ 16% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Global Institutional & Specialty increased in the third quarter and first nine months of 2022.

At an operating segment level, Institutional fixed currency sales increased 14% and 20% in the third quarter and first nine months of 2022, respectively, driven by accelerating total pricing and new business wins. Specialty fixed currency sales increased 8% and 6% in third quarter and first nine months of 2022, respectively, driven by strong quick service sales and modest growth in food retail sales.

Operating Income

Fixed currency operating income increased for both the third quarter and first nine months of 2022 while fixed currency operating income margins decreased and increased for the third quarter and first nine months of 2022, respectively, for our Global Institutional & Specialty segment.

Acquisition adjusted fixed currency operating income margins decreased 1.3 percentage points during the third quarter of 2022, as the 7.7 percentage point positive impacts from accelerating pricing were more than offset by the 8.6 percentage point negative impacts by higher Delivered Product Costs and investments in the business. Acquisition adjusted fixed currency operating income margins increased 0.3 percentage points during the first nine months of 2022, as the 8.7 percentage point positive impacts from accelerating total pricing and strong volume growth overcame the 8.5 percentage point negative impacts of higher Delivered Product Costs and investments in the business.

Global Healthcare & Life Sciences

​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​
Sales at fixed currency (millions) ​ ​ $375.5 ​ ​ ​ $279.7 ​ ​ ​ $1,138.9 ​ ​ ​ $852.8 ​
Sales at public currency (millions) ​ ​ 356.6 ​ ​ ​ 286.9 ​ ​ ​ 1,110.3 ​ ​ ​ 881.4 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ (9)% ​ ​ ​ ​ (8)% ​ ​ ​
Price changes ​ 9% ​ ​ ​ ​ 6% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ -% ​ ​ ​ ​ ​ ​ (2)% ​ ​ ​ ​
Acquisitions and divestitures ​ 34% ​ ​ ​ ​ 36% ​ ​ ​
Fixed currency sales change ​ 34% ​ ​ ​ ​ 34% ​ ​ ​
Foreign currency translation ​ ​ (9)% ​ ​ ​ ​ ​ ​ (6)% ​ ​ ​ ​
Public currency sales change ​ 24% ​ ​ ​ ​ 26% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $34.7 ​ ​ ​ $35.2 ​ ​ ​ $137.3 ​ ​ ​ $123.9 ​
Operating income at public currency (millions) ​ ​ 31.4 ​ ​ ​ 36.4 ​ ​ ​ 132.4 ​ ​ ​ 129.4 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ (1)% ​ ​ ​ ​ ​ ​ 11% ​ ​ ​ ​
Fixed currency operating income margin ​ 9.2% ​ 12.6% ​ 12.1% ​ 14.5%
Acquisition adjusted fixed currency operating income change ​ (46)% ​ ​ ​ ​ (42)% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 6.8% ​ 12.6% ​ 8.7% ​ 14.5%
Public currency operating income change ​ ​ (14)% ​ ​ ​ ​ ​ ​ 2% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Acquisition adjusted fixed currency sales for Global Healthcare & Life Sciences were flat for the third quarter, as growth in Life Sciences was offset by slightly lower Healthcare sales.

At an operating segment level, Healthcare fixed currency sales decreased 2% (2% acquisition adjusted) and 3% (5% acquisition adjusted) in the third quarter and first nine months of 2022, respectively, as accelerating total pricing was offset by continued softness in Europe. Life Sciences fixed currency sales increased 158% (5% acquisition adjusted) and 161% (6% acquisition adjusted) in the third quarter and first nine months of 2022, respectively, reflecting the acquisition of Purolite. Excluding the acquisition of Purolite, the Life Sciences business growth was driven by accelerating total pricing and double-digit growth in consumable pharmaceutical and personal care products were partially offset by normalizing demand for Bioquell’s biocontamination systems.

Operating Income

Fixed currency operating income decreased and increased for the third quarter and first nine months of 2022, respectively, while fixed currency operating income margins decreased for our Global Healthcare & Life Sciences segment in both the third quarter and first nine months of 2022.

Acquisition adjusted fixed currency operating income margins decreased 5.8 percentage points during the third quarter of 2022, as the 7.0 percentage point positive impacts from accelerated pricing was more than offset by the 13.7 percentage point negative impact from higher Delivered Product Costs, lower volumes and unfavorable mix. Acquisition adjusted fixed currency operating income margins decreased 5.8 percentage points during the first nine months of 2022, as the 4.5 percentage point positive impacts from impacts from accelerating pricing was more than offset by the 10.7 percentage point negative impact from higher Delivered Product Costs, lower volumes and investments in the business.

Other

​ ​ ​ ​ ​ ​ ​ ​ Third Quarter Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​
Sales at fixed currency (millions) ​ ​ $362.1 ​ ​ ​ $319.5 ​ ​ ​ $1,000.4 ​ ​ ​ $885.2 ​
Sales at public currency (millions) ​ ​ 352.3 ​ ​ ​ 324.2 ​ ​ ​ 987.4 ​ ​ ​ 900.4 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Volume ​ 6% ​ ​ ​ ​ 7% ​ ​ ​
Price changes ​ 7% ​ ​ ​ ​ 6% ​ ​ ​
Acquisition adjusted fixed currency sales change ​ ​ 13% ​ ​ ​ ​ ​ ​ 13% ​ ​ ​ ​
Acquisitions and divestitures ​ -% ​ ​ ​ ​ -% ​ ​ ​
Fixed currency sales change ​ 13% ​ ​ ​ ​ 13% ​ ​ ​
Foreign currency translation ​ ​ (4)% ​ ​ ​ ​ ​ ​ (3)% ​ ​ ​ ​
Public currency sales change ​ 9% ​ ​ ​ ​ 10% ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating income at fixed currency (millions) ​ ​ $64.4 ​ ​ ​ $57.8 ​ ​ ​ $153.6 ​ ​ ​ $140.9 ​
Operating income at public currency (millions) ​ ​ 63.0 ​ ​ ​ 58.7 ​ ​ ​ 152.1 ​ ​ ​ 143.3 ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Fixed currency operating income change ​ ​ 11% ​ ​ ​ ​ ​ ​ 9% ​ ​ ​ ​
Fixed currency operating income margin ​ 17.8% ​ 18.1% ​ 15.4% ​ 15.9%
Acquisition adjusted fixed currency operating income change ​ 11% ​ ​ ​ ​ 9% ​ ​ ​
Acquisition adjusted fixed currency operating income margin ​ 17.8% ​ 18.1% ​ 15.4% ​ 15.9%
Public currency operating income change ​ ​ 7% ​ ​ ​ ​ ​ ​ 6% ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Percentages in the above table do not necessarily sum due to rounding.

Net Sales

Fixed currency sales for Other increased in the third quarter and first nine months of 2022, reflecting double-digit growth in Pest Elimination, Textile Care, and Colloidal Technologies.

At an operating segment level, Pest Elimination fixed currency sales increased 12% and 11% in the third quarter and first nine months of 2022, respectively, reflecting strong growth across food retail, food and beverage, hospitality, and restaurants. Textile Care fixed currency sales increased 17% and 19% in the third quarter and first nine months of 2022, respectively. Colloidal Technologies Group fixed currency sales increased 16% and 13% in the third quarter and first nine months of 2022, respectively.

Operating Income

Fixed currency operating income increased and fixed currency operating income margins decreased for Other both in the third quarter and first nine months of 2022.

Acquisition adjusted fixed currency operating income margins decreased 0.3 percentage points during the third quarter of 2022, as the 5.6 percentage point positive impact from accelerating total pricing was more than offset by the 5.9 percentage point negative impact of higher Delivered Product Costs and investments in the business. Acquisition adjusted fixed currency operating income margins decreased 0.5 percentage points during the first nine months of 2022 as the 5.2 percentage point positive impact from accelerating pricing and volume growth was more than offset by the 5.4 percentage point negative impact of higher Delivered Product Costs and investments in business.

Corporate

Consistent with our internal management reporting, Corporate amounts in the table on page 39 include sales to ChampionX in accordance with the long-term supply agreement entered into with the Transaction post-separation, as discussed in Note 14, intangible asset amortization specifically from the Nalco and Purolite acquisitions and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 34.

FINANCIAL POSITION, CASH FLOWS AND LIQUIDITY

Financial Position

Total assets were $21.0 billion as of September 30, 2022, compared to total assets of $21.2 billion as of December 31, 2021.

Total liabilities were $13.9 billion as of September 30, 2022, compared to total liabilities of $14.0 billion as of December 31, 2021. Total debt was $8.5 billion as of September 30, 2022 and $8.8 billion as of December 31, 2021. See further discussion of our debt activity within the “Liquidity and Capital Resources” section of this MD&A.

Our net debt to earnings before interest, taxes, depreciation and amortization (“EBITDA”) is shown in the following table. EBITDA is a non-GAAP measure discussed further in the “Non-GAAP Financial Measures” section of this MD&A.

The inputs to EBITDA reflect the trailing twelve months of activity for the period presented:

​ ​ (ratio) ​ ​ ​ ​ September 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​
Net debt to EBITDA ​ 3.4 ​ ​ 3.4 ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
(millions) ​ ​ ​ ​ ​ ​ ​ ​
Total debt ​ ​ $8,524.6 ​ ​ ​ $8,758.2 ​ ​
Cash ​ 112.9 ​ ​ ​ 359.9 ​ ​
Net debt ​ ​ $8,411.7 ​ ​ ​ $8,398.3 ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net income including noncontrolling interest ​ ​ $1,144.7 ​ ​ ​ $1,144.0 ​ ​
Provision for income taxes ​ 226.6 ​ ​ ​ 270.2 ​ ​
Interest expense, net ​ 218.7 ​ ​ ​ 218.3 ​ ​
Depreciation ​ 614.7 ​ ​ ​ 604.4 ​ ​
Amortization ​ 303.1 ​ ​ ​ 238.7 ​ ​
EBITDA ​ $2,507.8 ​ ​ ​ $2,475.6 ​ ​

Cash Flows

Operating Activities

​ ​ ​ (millions) ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​
Cash provided by operating activities ​ ​ $929.2 ​ ​ ​ $1,421.0 ​ ​ ​ ($491.8) ​

We continue to generate cash flow from operations, allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases. Cash provided by operating activities decreased $492 million in first nine months of 2022 compared to the first nine months of 2021, driven primarily by $381 million increase in working capital excluding the impact of non-cash special charges. The increase in working capital is primarily driven by receivables higher than last year due to pricing and surcharge rollout but expected to improve by year-end. Additionally inventory was impacted by inflationary environment and higher stock holding to mitigate supply disruption.

Investing Activities

​ ​ ​ (millions) ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​
Cash used for investing activities ​ ​ ($506.4) ​ ​ ​ ($638.5) ​ ​ ​ $132.1 ​

Cash used for investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as capital investments in the business.

We continue to make capital investments in the business, including merchandising equipment, manufacturing equipment and facilities. Total capital expenditures were $510 million and $424 million in the first nine months of 2022 and 2021, respectively.

Total cash paid for acquisitions, net of cash acquired along with net cash received from dispositions, during the first nine months of 2022 and 2021, was $7 million and $210 million, respectively. Our acquisitions are discussed further in Note 3. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

Financing Activities

​ ​ ​ (millions) ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​
Cash used for financing activities ​ ​ ($675.6) ​ ​ ​ ($1,159.3) ​ ​ ​ $483.7 ​

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $88 million and $1 million of commercial paper and notes payable in the first nine months of 2022 and 2021, respectively. We issued $300 million par value and received $294 million in proceeds of long-term debt and repaid $900 million of long-term debt in the first nine months of 2021.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans, to manage our capital structure and to efficiently return capital to shareholders. We reacquired a total of $445 million and $78 million of shares in the first nine months of 2022 and 2021, respectively. Cash proceeds and tax benefits from stock option exercises provide a portion of the funding for repurchase activity.

We paid dividends of $445 million and $427 million in in the first nine months of 2022 and 2021, respectively.

The impact on financing cash flows of commercial paper and notes payable issuances are shown in the following table:

​ ​ ​ (millions) ​ ​ ​ ​ ​ Nine Months Ended September 30 2022 ​ ​ ​ ​ ​ 2021 ​ ​ ​ ​ Change ​ ​
Net issuances of commercial paper and notes payable ​ ​ $87.6 ​ ​ ​ $0.5 ​ ​ ​ $87.1 ​
Long-term debt borrowings ​ ​ - ​ ​ ​ 293.7 ​ ​ ​ (293.7) ​
Long-term debt repayments ​ ​ - ​ ​ ​ (1,017.9) ​ ​ ​ 1,017.9 ​

Liquidity and Capital Resources

We currently expect to fund the cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of September 30, 2022, we had $113 million of cash and cash equivalents on hand, of which $78 million was held outside of the U.S. We will continue to evaluate our cash position in light of future developments.

As of September 30, 2022, we have a $2.0 billion multi-year credit facility which expires in April 2026. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At the end of the third quarter of 2022, we had $485 million outstanding commercial paper under our U.S. program and no outstanding commercial paper under our Euro program. There were no borrowings under our credit facility as of September 30, 2022 or 2021. As of September 30, 2022, both programs were rated A-2 by Standard & Poor’s, P-2 by Moody’s and F-1 by Fitch.

There was no long-term debt issuance or repayment activity through the first nine months of 2022. Our long-term debt issuance and repayment activity through the first nine months of 2021 is discussed in the Cash Flows – Financing Activities section of this MD&A.

We are in compliance with our debt covenants and other requirements of our credit agreements and indentures. We believe we have sufficient borrowing capacity to meet our foreseeable operating activities, as needed.

The schedule of contractual obligations included in the Financial Position and Liquidity section of our Form 10-K for the year ended December 31, 2021 disclosed total notes payable and long-term debt due within one year of $11 million. As of September 30, 2022, the total notes payable and long-term debt due within one year was $13 million. There was $485 million commercial paper outstanding as of September 30, 2022 and $400 million as of December 31, 2021.

Our gross liability for uncertain tax positions was $20 million as of September 30, 2022 and $25 million as of December 31, 2021. We are not able to reasonably estimate the amount by which the liability will increase or decrease over time; however, at this time, we do not expect significant payments related to these obligations within the next year.

GLOBAL ECONOMIC ENVIRONMENT

Coronavirus disease 2019 (COVID-19)

In March 2020, the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization. The COVID-19 pandemic is continuing to affect major economic and financial markets and industries are facing the challenges with the economic conditions resulting from efforts to address the pandemic, including supply shortages, inflation and other challenges, such as those resulting from the introduction of vaccination mandates. While many government restrictions in the U.S. have eased, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a resurgence of cases triggering additional government mandated lockdowns or similar restrictions on activity, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world.

Global Economies

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results. We expect a more challenging macroeconomic environment, especially in Europe, as the war and the energy crisis is having a significant impact on costs and demand. We also assume continued high delivered product costs and significant unfavorable currency translation impacts that persist well into 2023.

Argentina is classified as a highly inflationary economy in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina. During the first nine months of 2022, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina at the end of the third quarter of 2022 represented less than 1% of our consolidated assets. Turkey was also classified as a highly inflationary economy in accordance with U.S. GAAP. During the first nine months of 2022, sales in Turkey represented less than 1% of our consolidated sales. Assets held in Turkey at the end of the third quarter of 2022 represented less than 1% of our consolidated assets.

In light of Russia’s invasion of Ukraine and the sanctions against Russia by the United States and other countries, we have made the determination that we will limit our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We may further narrow our presence in Russia depending on future developments. Our Russian and Ukraine operations represented approximately 1% of our 2021 annual sales. We recorded charges of $0.8 million in the third quarter of 2022 and $13.1 million in the first nine months of 2022 primarily related to recoverability risk of certain assets in both Russia and Ukraine.

NEW ACCOUNTING PRONOUNCEMENTS

For information on new accounting pronouncements, refer to Note 17 to the Consolidated Financial Statements.

Subsequent Events

In October 2022, we entered into a cross currency swap agreement with a notional amount of €200 million maturing in 2026. The cross currency swap is designated as a net investment hedge of our Euro denominated exposures from our investments in certain of its Euro denominated functional currency subsidiaries.

In November 2022, our Board of Director's authorized the repurchase up to 10 million additional shares of Ecolab common stock.

In November 2022, we announced a Europe cost savings program (the “Europe Program”) targeting $80 million of annualized pre-tax savings after completion of the program. The Europe Program is expected to be completed by mid-2024 and is expected to result in approximately $80 million of pre-tax annualized operating expense savings ($70 million after tax) by the end of 2024. In connection with these actions, we expect to incur pre-tax charges of $130 million ($110 million after tax), beginning with approximately $60 million of pre-tax charges in the fourth quarter of 2022. The Europe Program charges are expected to be primarily cash expenditures related to severance and asset disposals.

NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

  • Fixed currency sales
  • Acquisition adjusted fixed currency sales
  • Adjusted cost of sales
  • Adjusted gross margin
  • Fixed currency operating income
  • Fixed currency operating income margin
  • Adjusted operating income
  • Adjusted operating income margin
  • Adjusted fixed currency operating income
  • Adjusted fixed currency operating income margin
  • Acquisition adjusted fixed currency operating income
  • Acquisition adjusted fixed currency operating income margin
  • EBITDA
  • Adjusted tax rate
  • Adjusted net income attributable to Ecolab
  • Adjusted diluted EPS

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for cost of sales, gross margin and operating income exclude the impact of special (gains) and charges, and our non-GAAP measures for tax rate, net income attributable to Ecolab and diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as the sum of net income including noncontrolling interest, provision for income taxes, net interest expense, depreciation and amortization. EBITDA is used in our net debt to EBITDA ratio, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange. Fixed currency amounts included in this Form 10-Q are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2022. We also provide our segment results based on public currency rates for informational purposes.

Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated our reportable segments.

Acquisition adjusted growth rates exclude the results of our acquired businesses from the first twelve months post acquisition and exclude the results of our divested businesses from the twelve months prior to divestiture. In addition, as part of the separation of ChampionX in 2020, we entered into a Master Cross Supply and Product Transfer agreement with ChampionX to provide, receive or transfer certain products for a period up to 36 months. Sales of product to ChampionX under this agreement are recorded in product and equipment sales in the Corporate segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP, and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the COVID-19 pandemic outlook; business performance and prospects; expectations concerning timing, amount and type of restructuring costs and savings from restructuring activities; delivered product cost inflation, pricing actions, volume growth, cost savings and productivity improvements; Russian operations; tax deductibility of goodwill; capital investments, acquisitions and share repurchases; amortization expense; non-performance of financial counterparties; payments and contributions to pension and postretirement health care benefit plans; the impact of lawsuits, claims and environmental matters; impact of new accounting pronouncements; cash flows, borrowing capacity and funding of cash requirements; payments related to uncertain tax positions; and implementation of ERP system upgrade.

Without limiting the foregoing, words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “we believe,” “we expect,” “estimate,” “project” (including the negative or variations thereof) or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. In particular, the effects of the COVID-19 pandemic depend on numerous factors, including the severity of the disease, the duration of the outbreak, the distribution and efficacy of vaccines, the likelihood of a resurgence of the outbreak, including as result of emerging variants, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic, including vaccination mandates, or to stimulate the economy, and other unintended consequences. Further, the ultimate results of any restructuring or efficiency initiative, integration and business improvement actions, including cost synergies, depend on a number of factors, including the development of final plans, the impact of local regulatory requirements regarding employee terminations, the time necessary to develop and implement the restructuring or efficiency initiative and other business improvement initiatives and the level of success achieved through such actions in improving competitiveness, efficiency and effectiveness. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made.

Some of the factors which could cause results to differ materially from those expressed in any forward-looking statements are set forth under Item 1A of our most recent Form 10-K, as updated by Item 1A of this Form 10-Q, and our other public filings with the Securities and Exchange Commission (the "SEC"), and include the effects and duration of the COVID-19 pandemic, including the impact of vaccination mandates; difficulty in procuring raw materials or fluctuations in raw material costs; the vitality of the markets we serve; the impact of economic factors such as the worldwide economy, capital flows, interest rates, foreign currency risk, and reduced sales and earnings in our international operations resulting from the weakening of local currencies versus the U.S. dollar; information technology infrastructure failures or breaches in data security; our ability to attract, retain and develop high caliber management talent to lead our business and successfully execute organizational change and changing labor market dynamics in the wake of the COVID-19 pandemic; exposure to global economic, political and legal risks related to our international operations, including the impact of sanctions or other actions taken by the U.S. or other countries, and retaliatory measures taken by Russia in response, in connection with the conflict in Ukraine; public health outbreaks, epidemics or pandemics, such as the current outbreak of COVID-19; our ability to execute key business initiatives, including restructurings and our Enterprise Resource Planning system upgrades; our ability to successfully compete with respect to value, innovation and customer support; pressure on operations from consolidation of customers or vendors; restraints on pricing flexibility due to contractual obligations and our ability to meet our contractual commitments; realization of anticipated benefits of the Purolite acquisition; our ability to acquire complementary businesses and to effectively integrate such businesses; the costs and effects of complying with laws and regulations, including those relating to the environment and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; potential chemical spill or release; potential to incur significant tax liabilities or indemnification liabilities relating to the separation and split-off of our ChampionX business; the occurrence of litigation or claims, including class action lawsuits; the loss or insolvency of a major customer or distributor; repeated or prolonged government and/or business shutdowns or similar events; acts of war or terrorism; natural or man-made disasters; water shortages; severe weather conditions; changes in tax laws and unanticipated tax liabilities; potential loss of deferred tax assets; our indebtedness, and any failure to comply with covenants that apply to our indebtedness; potential losses arising from the impairment of goodwill or other assets; and other uncertainties or risks reported from time to time in our reports to the SEC. There can be no assurances that our earnings levels will meet investors’ expectations. Except as may be required under applicable law, we do not undertake, and expressly disclaim, any duty to update our Forward-Looking Statements.

Market risk

As filed, 555 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We use foreign currency forward contracts, interest rate swap agreements and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in our foreign operations. We do not hold derivative financial instruments of a speculative nature or for trading purposes. For a more detailed discussion of derivative instruments, refer to Note 8, entitled “Derivatives and Hedging Transactions”, of the consolidated financial statements located under Part I, Item 1 of this quarterly report on Form 10-Q.

Controls and procedures

As filed, 1,283 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As of September 30, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are effective.

During the period July 1, 2022 through September 30, 2022, other than with respect to the Purolite acquisition, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning (“ERP”) system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

Risk factors

As filed, 20,591 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In our report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 25, 2022, we identify under Item 1A important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q. See the section entitled Forward-Looking Statements located on page 49 of this Form 10-Q. We may also refer to such disclosure to identify factors that may cause results to differ from those expressed in other forward-looking statements made in oral presentations, including telephone conferences and/or webcasts open to the public.

The discussion below provides updates and additions to the risk factors and should be read together with the full list of risk factors set forth in the Form 10-K.

The COVID-19 pandemic and measures taken in response thereto have materially and adversely impacted, and we expect may continue to materially and adversely impact, our business and results of operations, and the full impact of the pandemic will depend on future developments, which are highly uncertain and cannot be predicted.

Beginning in March 2020, the COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. While many government restrictions in the U.S. have eased, restrictions on activities continue in many other regions, particularly those where vaccination rates lag, continuing to impact consumer activity in those regions. Concerns remain that our markets could see a resurgence of cases triggering additional government mandated lockdowns or similar restrictions on activity, for example due to the emergence of a variant against which existing vaccines are not as effective or which may be more easily transmitted, particularly to those unvaccinated. These conditions have had and will continue to have a negative impact on market conditions and customer demand throughout the world. In addition, the COVID-19 pandemic continues to have a material effect on the macroeconomic environment, including significant supply chain disruptions resulting from labor shortages, disruptions to logistics networks and capacity constraints, and there is continued uncertainty around its duration and ultimate impact.

We expect the full impact of the COVID-19 pandemic, including the extent of its effect on our business, results of operations and financial condition, to be dictated by future developments which remain uncertain and cannot be predicted, such as the severity of the disease, the duration of the outbreak, the distribution, acceptance and efficacy of vaccines, the likelihood of a resurgence of the outbreak, including as a result of emerging variants, actions that may be taken by governmental authorities intended to minimize the spread of the pandemic or to stimulate the economy and other unintended consequences. In addition to the reduction in the demand for our products and services, the COVID-19 pandemic has had, and we expect will continue to have, certain negative impacts on our business, including, but not limited to, the following:

  • We rely on a global workforce and take measures to protect the health and safety of our employees, customers and others with whom we do business while continuing to effectively manage our employees and maintain business operations. We have taken additional measures and incurred additional expenses to protect the health and safety of our employees to comply with applicable government requirements and safety guidance. Additionally, our business operations may be disrupted if a

significant portion of our workforce is unable to work safely and effectively due to illness, quarantines, government actions or other restrictions or measures responsive to the pandemic, or if members of senior management or our Board of Directors are unable to perform their duties for an extended period of time. A significant outbreak in one of our manufacturing facilities could adversely impact our ability to make and ship products in a timely manner. Measures taken across our business operations to address health and safety may not be sufficient to prevent the spread of COVID-19 among our employee base, customers and others. Therefore, we could face operational disruptions and incur additional expenses, including devoting additional resources to assisting employees diagnosed with COVID-19 and further changing health and safety protocols and processes, that could adversely affect our business and results of operations.

  • A significant number of our employees, as well as customers and others with whom we do business, continue to work in remote or hybrid mode in response to the COVID-19 pandemic. Our business operations may be disrupted, and we may experience increased risk of adverse effects to our business, if our business operations are negatively impacted as a result of remote work arrangements, including due to cybersecurity risks or other disruption to our technology infrastructure. Further, if our key operating facilities experience closures or worker shortages as a result of COVID-19, whether temporary or sustained, our business operations could be significantly disrupted.
  • We are subject to the mandatory vaccination and workplace safety protocols of Executive Order 14042 issued on September 9, 2021 and subsequent guidance issued thereunder by the Safer Federal Workforce Task Force. The Executive Order is currently stayed pending judicial review. This mandate, if enforceable, applies broadly to require covered federal contractor employees on covered contracts, those who perform duties in connection with a covered contract, and those working at the same workplace as covered employees, to be fully vaccinated for COVID-19, except for those that are legally entitled to an accommodation under applicable law. We may similarly be required to flow-down our obligations to certain of our subcontractors and suppliers. If it survives court challenge, the guidance remains subject to the interpretation of various government agencies and other entities, and questions remain regarding the specific application of the Executive Order and related guidance. As a result, if our understanding of its application to our workforce differs from our federal customers’ interpretation, or, despite our strong employee vaccination efforts, enough of our covered employees are unwilling to comply with the mandate, we may experience increased costs, business disruptions and attrition as a result of the mandate. Additionally, we may be subject to potential breach of contract claims, loss of business and assessment of fines if we or our affected subcontractors and suppliers are not able to fully comply in the time frame provided or if such subcontractors and suppliers choose to terminate their contract rather than comply.
  • Cost management and various cost-containment actions implemented across our business in response to the COVID-19 pandemic could hinder execution of our business strategy, including the deferral of planned capital expenditures, and could adversely affect our business and results of operations.
  • We believe that we appropriately reserve for expected credit losses; however, we cannot be certain that loss or delay in the collection of accounts receivable will not have a material adverse effect on our results of operations and financial condition.

Our results depend upon the continued vitality of the markets we serve.

Economic downturns, and in particular downturns in our larger markets including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our customers. In particular, we expect a more challenging macroeconomic environment, especially in Europe, as the war and the energy crisis are having a significant impact on costs and demand. Additionally, the last two years we have experienced the negative impact of the COVID-19 pandemic on the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In prior years, the weaker global economic environment has also negatively impacted certain of our end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in approximately 170 countries and, in 2021, approximately 48% of our net sales originated outside the United States. There are inherent risks in our international operations, including:

  • exchange controls and currency restrictions;
  • currency fluctuations and devaluations;
  • tariffs and trade barriers;
  • export duties and quotas;
  • changes in the availability and pricing of raw materials, energy and utilities;
  • changes in local economic conditions;
  • changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;
  • impact from Brexit and the possibility of similar events in other EU member states;
  • difficulties in managing international operations and the burden of complying with international and foreign laws;
  • requirements to include local ownership or management in our business;
  • economic and business objectives that differ from those of our joint venture partners;
  • exposure to possible expropriation, nationalization or other government actions;
  • restrictions on our ability to repatriate dividends from our subsidiaries;
  • unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict; and
  • countries whose governments have been hostile to U.S.-based businesses.

In light of Russia’s invasion of Ukraine and the United States’ and other countries’ sanctions against Russia, we announced in April 2022 that we will focus our Russian business on operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We may further narrow our presence in Russia depending on developments in the conflict or otherwise. Our Russian operations represented approximately 1% of our 2021 annual sales. In the first nine months of 2022, we recorded pre-tax charges of $13.1 million related to recoverability risk of certain assets in both Russia and Ukraine. Depending on developments, we may incur further charges relating to our Russia and Ukraine businesses. The conflict in Ukraine may escalate and/or expand in scope and the broader consequences of this conflict, which have included and/or may in the future include sanctions, embargoes, regional instability and geopolitical shifts; potential retaliatory action by the Russian government against companies, including us, such as nationalization of foreign businesses in Russia; and increased tensions between the United States and countries in which we operate cannot be predicted, nor can we predict the conflict’s impact on the global economy and on our business and financial results. The Russia and Ukraine conflict may also heighten many other risks disclosed in our report on Form 10-K, any of which could materially and adversely affect our business and financial results. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including increased inflation, constraints on the availability of commodities, supply chain disruption and decreased business spending; disruptions to our or our business partners’ global technology infrastructure, including through cyber-attack or cyber-intrusion; adverse changes in international trade policies and relations; claims, litigation and regulatory enforcement; our ability to implement and execute our business strategy; terrorist activities; our exposure to foreign currency fluctuations; reputational risk; and constraints, volatility, or disruption in the capital markets.

Additionally, changes in U.S. or foreign government policy on international trade, including the imposition or continuation of tariffs, could materially and adversely affect our business. In 2018, the U.S. imposed tariffs on certain imports from China and other countries, resulting in retaliatory tariffs by China and other countries. While the U.S. and China signed a Phase One trade agreement in January 2020, which included the suspension and rollback of tariffs, the CHIPS and Science Act of 2022 with objectives including countering China’s technical ambitions was signed into law in August 2022. Any new tariffs or policies imposed by the U.S., China or other countries or any additional retaliatory measures by any of these countries, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Further, our operations outside the United States require us to comply with a number of United States and non-U.S. laws and regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and non-U.S. economic sanctions regulations. We have internal policies and procedures relating to such laws and regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

If we are unsuccessful in executing on key business initiatives, including restructurings and our Enterprise Resource Planning (“ERP”) system upgrades, our business could be materially and adversely affected.

We continue to execute key business initiatives, including restructurings and investments to develop business systems, as part of our ongoing efforts to improve our efficiency and returns. In particular, we are currently undertaking the three restructuring plans, i.e., the Institutional Advancement Program, Accelerate 2020 and Europe Program, discussed under Note 2 entitled “Special (Gains) and Charges” of this Form 10-Q. Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. In particular, we are affected by the impact of changes to tax laws or related authoritative interpretations in the United States, such as the Inflation Reduction Act signed into law on August 16, 2022, which includes a corporate alternative minimum tax on certain large corporations, incentives to address climate change mitigation and other non-income tax provisions, including an excise tax on the repurchase of corporate stock. We are also subject to changes in tax law outside the United States and actions taken with respect to tax-related matters by associations such as the Organization for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries, and the European Commission which influence tax policies in countries where we operate. For example, approximately 140 countries have agreed to the OECD’s two-pillar base erosion and profit shifting project (“BEPS”). This framework, which could be implemented in some countries as early as 2023, is focused on a number of issues, including shifting taxing rights on income from residence countries to source countries and establishing a minimum 15% global tax rate. Some of the BEPS and related proposals, if enacted into law in the United States and in the foreign countries where we do business, could increase the burden and costs of our tax compliance, the amount of taxes we incur in those jurisdictions and our global effective tax rate. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial statements.

As of September 30, 2022, we had approximately $8.5 billion in outstanding indebtedness, with approximately $2.0 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

  • requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;
  • reducing our flexibility in planning for or reacting to changes in our business and market conditions;
  • exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at September 30, 2022 would increase future interest expense by approximately $20 million per year; and
  • increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$3.67bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$10.52bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2022-07-01 to 2022-09-30$2.29bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2022-01-01 to 2022-09-30$6.58bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2022-07-01 to 2022-09-30$876.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2022-01-01 to 2022-09-30$2.73bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-07-01 to 2022-09-30$483.0mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30$1.16bnus-gaap:OperatingIncomeLoss
Interest expense3 months2022-07-01 to 2022-09-30$66.7mus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-09-30$179.1mus-gaap:InterestExpense
Income tax3 months2022-07-01 to 2022-09-30$60.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$182.4mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30$347.1mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30$827.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30$1.21us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30$2.88us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30$1.22us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30$2.90us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-30286,300,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-30287,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30$929.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$510.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2022-01-01 to 2022-09-30$445.0mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2022-01-01 to 2022-09-30$445.4mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2022-09-30$112.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$5.10bnus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$21.04bnus-gaap:Assets
Current liabilitiesAt period end2022-09-30$3.77bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$13.95bnus-gaap:Liabilities
Current portion of debtAt period end2022-09-30$497.9mus-gaap:DebtCurrent
Shareholders' equityAt period end2022-09-30$7.06bnus-gaap:StockholdersEquity
Shares outstandingAt period end2022-09-30284,828,060 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001558370-22-016340. Last ingested by Listed: Nov 13, 2026, 16:24 ET. Listed shows no prices and gives no investment advice.